Evidence map›Paper›PMID 39817192›Full record

ArticleMolecular therapy. Nucleic acids2025

Harnessing defective interfering particles and lipid nanoparticles for effective delivery of an anti-dengue virus RNA therapy.

Min-Hsuan Lin, Pramila Maniam, Dongsheng Li, Bing Tang, Cameron R Bishop, Andreas Suhrbier, Lucy Wales- Earl, Yaman Tayyar, Nigel A J McMillan, Li Li and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Nucleic acids, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Min-Hsuan LinProgram of Infection and Inflammation, QIMR Berghofer Medical Research Institute, Herston, QLD 4006, Australia.
Pramila ManiamProgram of Infection and Inflammation, QIMR Berghofer Medical Research Institute, Herston, QLD 4006, Australia.
Dongsheng LiProgram of Infection and Inflammation, QIMR Berghofer Medical Research Institute, Herston, QLD 4006, Australia.
Bing TangProgram of Infection and Inflammation, QIMR Berghofer Medical Research Institute, Herston, QLD 4006, Australia.
Cameron R BishopProgram of Infection and Inflammation, QIMR Berghofer Medical Research Institute, Herston, QLD 4006, Australia.
Andreas SuhrbierProgram of Infection and Inflammation, QIMR Berghofer Medical Research Institute, Herston, QLD 4006, Australia.
Lucy Wales- EarlMenzies Health Institute Queensland and School of Pharmacy and Medical Science, Griffith University, Gold Coast, QLD 4222, Australia.
Yaman TayyarMenzies Health Institute Queensland and School of Pharmacy and Medical Science, Griffith University, Gold Coast, QLD 4222, Australia.
Nigel A J McMillanMenzies Health Institute Queensland and School of Pharmacy and Medical Science, Griffith University, Gold Coast, QLD 4222, Australia.
Li LiAustralian Institute for Bioengineering and Nanotechnology, the University of Queensland, St Lucia, QLD 4072, Australia.
David HarrichProgram of Infection and Inflammation, QIMR Berghofer Medical Research Institute, Herston, QLD 4006, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Currently, no approved antiviral drugs target dengue virus (DENV) infection, leaving treatment reliant on supportive care. DENV vaccine efficacy varies depending on the vaccine type, the circulating serotype, and vaccine coverage. We investigated defective interfering particles (DIPs) and lipid nanoparticles (LNPs) to deliver DI290, an anti-DENV DI RNA. Both DIPs and DI290-loaded LNPs (LNP-290) effectively suppressed DENV infection in human primary monocyte-derived macrophages (MDMs), THP-1 macrophages, and fibroblasts-natural DENV targets. Inhibiting interferon (IFN) signaling with a Janus kinase 1/2 inhibitor or an IFN-α/β receptor 1 (IFNAR1)-binding antibody blocked DIP and LNP-290 antiviral activity. LNP-290 demonstrated a greater than log10 inhibition of DENV viral loads in IFNAR-deficient (

Indexed as

antiviraldefectivedengueDIPsinterferingLNPsmouseMT: Delivery StrategiesRNAtherapeutic

Identifiers

PMID39817192
PMCPMC11733052

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.